Personalized and Adaptive Breast Cancer Treatment System

A next-generation breast cancer treatment system that leverages machine learning, gene editing, and real-time monitoring to provide personalized and adaptive therapy, overcoming the limitations of traditional treatments.

The original patent disclosed a nanomedicinal composition for treating breast cancer, but it had limitations in terms of personalized treatment and real-time adaptation. The new inventive concept addresses these limitations by integrating machine learning, gene editing, and real-time monitoring to provide a more effective and targeted treatment approach.

The new inventive concept comprises a system for personalized breast cancer treatment, which includes a nanocarrier with a porous silicate matrix and particles of a magnetic ferrite, a pharmaceutical agent mixture comprising an anti-cancer therapeutic and an antioxidant, and a machine learning algorithm configured to optimize the pharmaceutical agent mixture based on the subject's genetic profile. The system can also adjust the pharmaceutical composition in real-time based on the subject's response to treatment. Additionally, the system can be integrated with gene editing tools and miniature electromagnetic coils for targeted and in-situ treatment. The system's real-time monitoring capabilities enable early detection of breast cancer and prevention of the disease.

The new claims introduce several novel and non-obvious features, including the integration of machine learning and gene editing tools, real-time monitoring and adaptation, and in-situ treatment capabilities. These features overcome the limitations of traditional breast cancer treatments and provide a more effective and targeted approach.

Alternative embodiments of the inventive concept could include using different types of nanoparticles or gene editing tools, or integrating the system with other diagnostic or therapeutic modalities. Variations of the system could also be developed for treating other types of cancer or diseases.

The inventive concept has significant commercial potential in the field of personalized medicine and cancer treatment. The system could be marketed to hospitals, clinics, and research institutions, and could also be used in conjunction with other diagnostic or therapeutic modalities. The market potential is significant, with the global cancer treatment market projected to reach $150 billion by 2025.